HPV linked to rare sinonasal cancers in new study
NCT ID NCT04979000
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 49 people with sinonasal cancer to see if high-risk HPV, tobacco, alcohol, or drug use play a role. Researchers tested tumor samples for HPV and compared risk factors by gender and race. The goal is to better understand what causes these rare cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could clarify how HPV and lifestyle factors contribute to sinonasal cancers, potentially guiding future prevention or screening strategies.
- What could go wrong
- This is a small, completed observational study (49 participants) that looks back at existing data, so it cannot prove cause and effect or directly lead to a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- Rare sinus cancer study aims to clarify treatment outcomes
- Radiation-Free hope: study tests if surgery alone is enough for rare nasal cancer
- New drug duo aims to make inoperable sinus cancer removable
- Experimental immune therapy aims to tackle HPV cancers before standard care